It is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist)
Because of its established effectiveness, low risk profile, and affordability, metformin is usually the first-choice medication for those with type 2 diabetes.Empagliflozin, however, offers additional benefits, such as cardiovascular protection and weight loss, which may be particularly advantageous for certain patients
The main area of application of these drugs is treating various metabolic disorders, such as type 2 diabetes, obesity, and other metabolic diseases
Effect of dietary supplementation with oat -glucan for 3 months in subjects with type 2 diabetes: a randomized, double-blind, controlled clinical trial